DFFN
Income statement / Annual
Last year (2022), Diffusion Pharmaceuticals Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Diffusion Pharmaceuticals Inc.'s net income was -$15.21 M.
See Diffusion Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$71,667.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$89,387.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$17,720.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0.25 |
| Research and Development
Expenses |
$7.24 M
|
$8.50 M
|
$9.43 M
|
$6.62 M
|
$5.75 M
|
$5.09 M
|
$7.25 M
|
$3.85 M
|
$2.86 M
|
$3.53 M
|
| General & Administrative
Expenses |
$8.74 M
|
$7.45 M
|
$6.44 M
|
$4.83 M
|
$6.17 M
|
$6.19 M
|
$11.09 M
|
$8.88 M
|
$4.76 M
|
$3.08 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.74 M
|
$7.45 M
|
$6.44 M
|
$4.83 M
|
$6.17 M
|
$6.19 M
|
$11.09 M
|
$8.88 M
|
$4.76 M
|
$3.08 M
|
| Other Expenses |
$0.00 |
$93,416.00 |
$103,168.00 |
$97,915.00 |
$110,371.00 |
$11.85 M |
$0.00 |
$6,357.00 |
-$2.28 M |
$265,223.00 |
| Operating Expenses |
$15.97 M |
$16.04 M |
$15.97 M |
$11.55 M |
$12.03 M |
$11.35 M |
$18.37 M |
$12.76 M |
$7.94 M |
$6.83 M |
| Cost And Expenses |
$15.97 M |
$16.04 M |
$15.97 M |
$11.55 M |
$12.03 M |
$11.35 M |
$18.37 M |
$12.76 M |
$7.94 M |
$6.83 M |
| Interest Income |
$380,752.00 |
$137,487.00 |
$114,257.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$151,647.00 |
$48,006.00 |
$29,686.00 |
$0.00 |
$273,503.00 |
$228,294.00 |
| Depreciation &
Amortization |
-$208,577.00
|
$17.37 M
|
$103,168.00
|
$97,915.00
|
$110,371.00
|
$67,981.00
|
$25,342.00
|
$23,269.00
|
$566,262.00
|
$675,757.00
|
| EBITDA |
-$15.97 M
|
-$7.31 M
|
-$15.87 M
|
$11.55 B
|
$18.96 M
|
$11.35 M
|
$18.37 M
|
-$1.66 M
|
-$9.66 M
|
-$14.10 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-81.1 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-180.24
|
| Total Other
Income/Expenses Net |
$380,752.00
|
$137,487.00
|
$114,257.00
|
$85,302.00
|
-$37.77 M
|
-$13.77 M
|
-$36.77 M
|
$6,357.00
|
-$2.56 M
|
$10.46 M
|
| Income Before Tax |
-$15.59 M |
-$24.54 M |
-$15.86 M |
-$11.47 M |
-$18.81 M |
-$2.42 M |
-$18.40 M |
-$23.82 M |
-$17.17 M |
-$2.46 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-34.3
|
| Income Tax Expense |
-$380,752.00 |
-$443,893.00 |
-$1.68 M |
$332,885.00 |
-$437,289.00 |
-$1.06 M |
-$364,796.00 |
$11.07 M |
-$2.82 M |
$499,918.00 |
| Net Income |
-$15.21 M |
-$24.10 M |
-$14.19 M |
-$11.80 M |
-$18.37 M |
-$1.36 M |
-$18.04 M |
-$23.82 M |
-$14.35 M |
-$2.46 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-34.39 |
| EPS |
-7.46 |
-18.57 |
-19.76 |
-131.95 |
-283.28 |
-82.44 |
-1322.04 |
-6819.55 |
-7530.34 |
-3179.81 |
| EPS Diluted |
-11.19 |
-18.57 |
-19.76 |
-131.95 |
-283.28 |
-80.45 |
-1322.04 |
-6819.55 |
-7530.34 |
-3179.81 |
| Weighted Average Shares
Out |
$2.04 M
|
$1.30 M
|
$717,759.00
|
$89,420.00
|
$64,846.00
|
$16,551.00
|
$13,643.00
|
$3,493.00
|
$1,906.00
|
$775.00
|
| Weighted Average Shares
Out Diluted |
$1.36 M
|
$1.30 M
|
$717,759.00
|
$89,420.00
|
$64,846.00
|
$16,961.00
|
$13,643.00
|
$3,493.00
|
$1,906.00
|
$775.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
